The Role of Gefitinib in Treating Non-Small Cell Lung Cancer and Mutated Lung Cancer
Non-small Cell Lung Cancer (NSCLC) is the most common type of lung cancer.
And in only 10% of the cases, EGFR mutations are observed.
And gefitinib is generally recommended to people who have the most common type of EGFR mutations.
See More: https://shorturl.at/vKR12
#Gefitinib #NSCLC #LungCancerTreatment #MutatedLungCancer #TargetedTherapy #PrecisionMedicine #cancerresearch #Oncology #PersonalizedMedicine #MedicalAdvancements
Non-small Cell Lung Cancer (NSCLC) is the most common type of lung cancer.
And in only 10% of the cases, EGFR mutations are observed.
And gefitinib is generally recommended to people who have the most common type of EGFR mutations.
See More: https://shorturl.at/vKR12
#Gefitinib #NSCLC #LungCancerTreatment #MutatedLungCancer #TargetedTherapy #PrecisionMedicine #cancerresearch #Oncology #PersonalizedMedicine #MedicalAdvancements
02:36 AM - Feb 17, 2024
Only people mentioned by 911GlobalMeds in this post can reply
